Sign in Sign up for free

Last updated: 8 September 2023 at 5:01pm EST

David Grayzel Net Worth




The estimated Net Worth of David S. Grayzel is at least $34 Million dollars as of 17 December 2020. David Grayzel owns over 1,700,000 units of Surface Oncology Inc stock worth over $3,151,635 and over the last 6 years he sold SURF stock worth over $30,770,000. In addition, he makes $69,457 as Independent Director at Surface Oncology Inc.

David Grayzel SURF stock SEC Form 4 insiders trading

David has made over 2 trades of the Surface Oncology Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 1,700,000 units of SURF stock worth $30,770,000 on 17 December 2020.

The largest trade he's ever made was selling 1,700,000 units of Surface Oncology Inc stock on 17 December 2020 worth over $30,770,000. On average, David trades about 200,000 units every 108 days since 2018. As of 17 December 2020 he still owns at least 2,945,453 units of Surface Oncology Inc stock.

You can see the complete history of David Grayzel stock trades at the bottom of the page.





David Grayzel biography

Dr. David Grayzel is Independent Director of the Company. Dr. Grayzel has also served as our Chief Executive Officer from April 2014 to May 2015, and Chairman of our board of directors from April 2014 to January 2017. Dr. Grayzel has been a Partner at Atlas Venture Inc. since April 2014. Since joining Atlas Venture Inc. in June 2010, Dr. Grayzel co-founded and served as Chief Executive Officer of Arteaus Therapeutics, LLC from June 2011 until it was acquired by Eli Lilly and Company in January 2014, served as co-founder and Chief Executive Officer of Annovation Biopharma, Inc. from May 2011 until it was acquired by The Medicines Company in February 2015, and a founding board member of Delinia, Inc. from September 2015 until it was acquired by Celgene Corporation in January 2017. He is a co-founder and currently a member of the board of directors of Cadent Therapeutics, Inc., and a board member of Xilio and Affinia Therapeutics. Previously, he was a member of the executive team at Infinity Pharmaceuticals as the head of clinical development. Dr. Grayzel serves on the board of Acera School, Inc. (The Massachusetts School for Science, Creativity, and Leadership). He also serves as an advisor to several organizations including Memorial Sloan Kettering Cancer Center’s (MSKCC) Technology Development Fund, the American Heart Association’s One Brave Idea, and is on the Scientific Advisory Board of the Tri-TDI that includes Rockefeller University, MSKCC, and Cornell. Dr. Grayzel received a B.A. in Psychology from Stanford University, an M.D. from Harvard Medical School, and completed his internship and residency training in Internal Medicine at Massachusetts General Hospital. Our board of directors believes that Dr. Grayzel’s experience working with and serving on the boards of directors of life sciences companies and his experience working in the venture capital industry qualify him to serve on our Board of Directors.

What is the salary of David Grayzel?

As the Independent Director of Surface Oncology Inc, the total compensation of David Grayzel at Surface Oncology Inc is $69,457. There are 9 executives at Surface Oncology Inc getting paid more, with J. Jeffrey Goater having the highest compensation of $1,642,260.



How old is David Grayzel?

David Grayzel is 52, he's been the Independent Director of Surface Oncology Inc since 2017. There are 4 older and 11 younger executives at Surface Oncology Inc. The oldest executive at Surface Oncology Inc is Elliott Sigal, 68, who is the Independent Director.

What's David Grayzel's mailing address?

David's mailing address filed with the SEC is C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE, MA, 02139.

Insiders trading at Surface Oncology Inc

Over the last 6 years, insiders at Surface Oncology Inc have traded over $69,198,912 worth of Surface Oncology Inc stock and bought 2,836,996 units worth $42,496,090 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Surface Oncology Inc executives and independent directors trade stock every 37 days with the average trade being worth of $156,856. The most recent stock trade was executed by Alison Oneill on 1 August 2023, trading 7,042 units of SURF stock currently worth $6,619.



What does Surface Oncology Inc do?

surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww



What does Surface Oncology Inc's logo look like?

Surface Oncology Inc logo

Complete history of David Grayzel stock trades at Surface Oncology Inc

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
17 Dec 2020 SURF Surface Oncology Inc David S. Grayzel
Director
 Sale 1,700,000 $18.10 $30,770,000
17 Dec 2020
2,945,453 ↗
23 Apr 2018 SURF Surface Oncology Inc David S. Grayzel
Director
 Buy 100,000 $15.00 $1,500,000
23 Apr 2018
4,645,453 ↗


Surface Oncology Inc executives and stock owners

Surface Oncology Inc executives and other stock owners filed with the SEC include: